About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Clinicaltrials.gov identifier NCT03941483

Recruitment Status Recruiting

First Posted May 8, 2019

Last update posted October 7, 2020

Study Description

Brief summary:

The purpose of this study is to evaluate the efficacy of postsurgery treatment with ASP1128 in subjects at risk for acute kidney injury (AKI) following CABG and/or valve surgery. This study will also investigate the safety and tolerability of postsurgery treatment with ASP1128, and pharmacokinetic characteristics of ASP1128 in subjects at risk for AKI following CABG and/or valve surgery.

  • Condition or Disease:Acute Kidney Injury (AKI)
  • Intervention/Treatment: Drug: ASP1128
    Drug: Placebo
  • Phase: Phase 2
Detailed Description

The study will comprise a screening visit, followed by CABG and/or valve surgery on Day 1, double-blind treatment period and a follow-up period up to Day 90 in subjects with moderate/severe risk of AKI (acute kidney injury) at 2-6 hours post-surgery. Subjects with low risk of AKI at 2-6 hour post-surgery assessment will be enrolled in the observational cohort to evaluate subject characteristics and biomarkers for exploratory objectives.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 220 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
  • Actual Study Start Date: November 2019
  • Estimated Primary Completion Date: January 2022
  • Estimated Study Completion Date: March 2022
Arms and interventions
Arm Intervention/treatment
Experimental: ASP1128
Participants will receive ASP1128 solution intravenously once daily for 3 days.
Drug: ASP1128
Intravenous
Placebo Comparator: Matching placebo
Participants will receive matching placebo solution intravenously once daily for 3 days.
Drug: Placebo
Intravenous
Outcome Measures
  • Primary Outcome Measures: 1. Proportion of participants developing acute kidney injury based on serum creatinine (SCr) criteria within 72 hrs (AKI-SCr72h) [ Time Frame: Up to 72 hrs ]
    Development of AKI will be judged based on SCr criteria from the kidney disease: improving global outcomes (KDIGO) guideline (i.e., increase in SCr ≥ 0.3 mg/dL [≥ 26.5 μmol/L] from baseline within 48 hours after end of surgery (T0), or increase in SCr to ≥ 1.5 times baseline within 72 hours after T0).
  • Secondary Outcome Measures: 1. Proportion of participants developing AKI based on SCr criteria within 7 days (AKI-SCr7d) [ Time Frame: Up to Day 7 ]
    Development of AKI will be judged based on SCr criteria from KDIGO guideline (i.e., increase in SCr ≥ 0.3 mg/dL [≥ 26.5 μmol/L] from baseline within any 48 hours after T0, or increase in SCr to ≥ 1.5 times baseline within 7 days after T0).
  • 2. Proportion of participants developing AKI based on all captured criteria within 72 hours (AKI-KDIGO72h) [ Time Frame: Up to 72 hrs ]
    Development of AKI will be judged based on all captured criteria from KDIGO guideline (i.e., AKI-SCr stage 1 to 3: increase in SCr ≥ 0.3 mg/dL [≥ 26.5 μmol/L] from baseline within 48 hours after T0, increase in SCr to ≥ 1.5 times baseline within 72 hours after T0, and/or AKI-urinary output (UO) stage 2 and 3: urine volume < 0.5 mL/kg per hour for 12 consecutive hours within 72 hours after T0).
  • 3. Proportion of participants developing AKI based on all criteria within 7 days (AKI-KDIGO7d) [ Time Frame: Up to Day 7 ]
    Development of AKI will be judged based on all criteria from KDIGO guideline within 7 days after T0.
  • 4. Proportion of participants with major adverse kidney events (MAKE) within 30 days (MAKE30) [ Time Frame: Up to Day 30 ]
    MAKE30 is defined as all-cause mortality, renal replacement therapy (RRT) and/or ≥ 25% sustained reduction in estimated glomerular filtration rate (eGFR) based on SCr within 30 days after day of surgery.
  • 5. Proportion of participants with MAKE within 90 days (MAKE90) [ Time Frame: Up to Day 90 ]
    MAKE90 is defined as all-cause mortality, RRT and/or ≥ 25% sustained reduction in eGFR based on SCr within 90 days after day of surgery.
Eligibility Criteria
  • Ages Eligible for Study: 35 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Subject agrees not to participate in another interventional study after signing the
informed consent form and until the end of study (EoS) visit has been completed.

- Subject is ≥ 35 years of age at the time of screening (visit 1).

- Subject undergoing non-emergent open chest cardiovascular surgery with the use of
cardiopulmonary bypass pump (CPB) (i.e., coronary artery bypass graft (CABG) and/or
valve surgery [including aortic root and ascending aorta surgery without circulatory
arrest]) within 4 weeks of screening (visit 1).

- Subject is at risk of developing acute kidney injury (AKI) following cardiovascular
surgery, i.e., has 1 or more of the following AKI risk factors:

- Age at screening of ≥ 70 years

- Documented history of eGFR < 60 mL/min per 1.73 m^2 as per Modification of Diet in Renal Disease Study (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (or documented measured glomerular filtration rate assessment) (history needs to be present for at least 90 days prior to screening, and eGFR at screening or baseline needs to be < 60 mL/min per 1.73 m^2, as well as per CKD-EPI equation.) - Documented history of congestive heart failure requiring hospitalization. This condition should exist for ≥ 90 days prior to screening. - Documented history of diabetes mellitus (type 1 or 2) of ≥ 90 days prior to screening, and subject is on active antidiabetic medication treatment for ≥ 90 days. - Documented history of proteinuria/albuminuria at any time point before screening (urinary dipstick result of ≥ 2+, documented urinary albumin creatinine ratio measurement of ≥ 300 mg/g, or documented total quantity of protein in a 24-hour urine collection test ≥ 0.3 g/day) - Subject must have the ability and willingness to return for all scheduled visits and perform all assessments. - Female subject is eligible to participate if she is not pregnant and at least 1 of the following conditions applies: - Not a woman of childbearing potential (WOCBP), OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 30 days after the final study drug administration. - Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 30 days after the final study drug administration. - Female subject must not donate ova starting at screening and throughout the study period, and for 30 days after the final study drug administration. - Male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 30 days after the final study drug administration. - Male subject must not donate sperm during the treatment period and for at least 30 days after the final study drug administration. - Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 30 days after the final study drug administration. Exclusion Criteria: At Screening: - Subject has received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening. - Subject has received RRT within 30 days prior to screening. - Subject has CKD stage 4 or 5, or stage 3 (i.e., eGFR 30-59 mL/min per 1.73m^2) with a known history of eGFR 2 times the
upper limit of normal (ULN) or bilirubin increased to > 1.5 times the ULN.

- eGFR < 30 mL/min per 1.73 m^2 as per CKD-EPI equation. - Subject has use of left ventricular assist device, intra-aortic balloon pump or other cardiac devices, or catecholamines within 7 days prior to screening. - Subject has surgery scheduled to be performed without CPB (i.e., "Off-Pump" surgery). - Subject has surgery scheduled to be performed under conditions of circulatory arrest, including planned deep hypothermic circulatory arrest. - Subject has surgery scheduled for aortic dissection. - Subject has surgery for a condition that is immediately life-threatening. - Subject has surgery scheduled to correct major congenital heart defect. - Subject has current or previous malignant disease. Subjects with a history of cancer are considered eligible if the subject has undergone therapy and the subject has been considered disease free or progression free for at least 5 years. Subject with completely excised basal cell carcinoma or squamous cell carcinoma of the skin and completely excised cervical cancer in situ are also considered eligible. Preoperatively on the Day of Surgery: - Exclusion criteria 1 to 17 are applicable at this time. - Subject has AKI (any stage) present at presurgery baseline. - Subject has known or suspected infection/sepsis at time of presurgery baseline. Perioperative Exclusion Criteria: - Subject requires Extracorporeal Membrane Oxygenation during or after completion of surgery. - Subject requires ventricular assist device during or after completion of surgery. - Subject has surgery performed "Off-Pump" at any time during surgery. General: - Subject has other condition, which makes the subject unsuitable for study participation. - Female subject who is pregnant or lactating or has a positive pregnancy test within 72 hours prior to screening and/or randomization, has been pregnant within 6 months before screening assessment or breastfeeding within 3 months before screening or who is planning to become pregnant within the total study period. - Subject has a known or suspected hypersensitivity to ASP1128 or any components of the formulation used.

Contacts and Locations
Contacts

Contact: Astellas Pharma Inc. 800-888-7704 Astellas.registration@astellas.com

Locations
Show 32 Study Locations
Sponsors and Collaborators

Astellas Pharma Inc

Investigators

Study Director: Senior Director Astellas Pharma Inc

More Information
  • Responsible Party: Astellas Pharma Inc
  • ClinicalTrials.gov Identifier: NCT03941483 History of Changes
  • Other Study ID Numbers: 1128-CL-0201
  • First Posted: May 8, 2019 Key Record Dates
  • Last Update Posted: October 7, 2020
  • Last Verified: October 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)
  • Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
  • Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
  • URL: https://clinicalstudydatarequest.com
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Acute Kidney Injury Wounds and Injuries